Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $24.30.

A number of brokerages have issued reports on ALHC. Wolfe Research assumed coverage on Alignment Healthcare in a research note on Friday, April 17th. They issued an “outperform” rating and a $24.00 price objective for the company. UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a report on Wednesday. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Weiss Ratings upgraded shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, May 7th.

Insider Activity

In other news, CEO John E. Kao sold 298,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $20.36, for a total transaction of $6,067,280.00. Following the completion of the sale, the chief executive officer owned 1,386,766 shares in the company, valued at $28,234,555.76. This trade represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $16.09, for a total transaction of $482,700.00. Following the completion of the sale, the president directly owned 998,813 shares in the company, valued at $16,070,901.17. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 854,250 shares of company stock worth $16,396,606. 5.20% of the stock is owned by insiders.

Institutional Trading of Alignment Healthcare

Several hedge funds have recently made changes to their positions in the company. Summit Securities Group LLC bought a new position in shares of Alignment Healthcare during the 4th quarter worth $26,000. Versant Capital Management Inc lifted its holdings in Alignment Healthcare by 463.3% during the second quarter. Versant Capital Management Inc now owns 1,380 shares of the company’s stock valued at $33,000 after purchasing an additional 1,135 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares during the last quarter. Larson Financial Group LLC purchased a new stake in Alignment Healthcare during the third quarter valued at about $33,000. Finally, First Horizon Corp bought a new position in Alignment Healthcare during the fourth quarter worth about $39,000. 86.19% of the stock is currently owned by institutional investors.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Negative Sentiment: Several plaintiff firms, including Kirby McInerney, Frank R. Cruz, Block & Leviton, Johnson Fistel, and Hagens Berman, announced investigations into possible securities fraud and whistleblower allegations involving Alignment Healthcare. Article: ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
• Negative Sentiment: Reports that a former executive filed a whistleblower lawsuit alleging deliberate accounting irregularities and financial manipulation triggered a sharp selloff and the stock’s worst move in more than two years. Article: ALHC Stock Clocks Worst Day In Over 2 Years On Whistleblower Financial Manipulation Allegation
• Negative Sentiment: Zacks Research downgraded ALHC from “strong-buy” to “hold,” adding another bearish signal for investors. Article: Zacks Research downgrade coverage
• Neutral Sentiment: Alignment Healthcare said it will report second-quarter 2026 results on July 30, which gives investors a near-term catalyst for clarity on fundamentals and any fallout from the allegations. Article: Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
• Neutral Sentiment: One Zacks commentary highlighted AI automation and complex-care growth as potential long-term operational positives, but this was overshadowed by the fraud-related headlines. Article: ALHC Trends to Watch as AI Automation Reshapes Medicare Economics

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC opened at $21.03 on Friday. Alignment Healthcare has a twelve month low of $11.63 and a twelve month high of $25.12. The stock’s 50 day moving average price is $19.11 and its 200-day moving average price is $19.79. The company has a market capitalization of $4.35 billion, a PE ratio of 233.67, a PEG ratio of 2.70 and a beta of 1.05. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 1.56.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, April 30th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.Alignment Healthcare’s quarterly revenue was up 33.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share. On average, equities analysts anticipate that Alignment Healthcare will post 0.2 EPS for the current year.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.